3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Temozolomide
48
Radiotherapy
26
Radiation
13
Chemotherapy, Adjuvant
9
O(6)-benzylguanine
8
Irinotecan
8
Carmustine
8
Surgical Procedures, Operative
7
Magnetic Resonance Spectroscopy
6
Erlotinib Hydrochloride
6
motexafin gadolinium
5
Radiotherapy, Intensity-Modulated
5
Imatinib Mesylate
5
sargramostim
4
Radiotherapy, Conformal
4
Hydroxyurea
4
Gene Expression Profiling
4
lonafarnib
3
Radiosurgery
3
Immunohistochemistry
3
Genetic Therapy
3
Filgrastim
3
Drug Therapy
3
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
3
vandetanib
2
tipifarnib
2
temsirolimus
2
cediranib
2
aldesleukin
2
Vorinostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Gliosarcoma
×
Oncolytic Virotherapy
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled